Key Takeaways
- • Sovereign wealth funds invested $14.2 billion in mainland China and Hong Kong in the first nine months of 2026, a 190% surge compared with their full-year 2025 total, according to Singapore-based consultancy Global SWF.
- • Saudi Arabia's Public Investment Fund led the inflows with $6 billion, followed by Abu Dhabi Investment Authority at $2.5 billion, Mubadala at $800 million and Qatar Investment Authority at $600 million; the four Gulf funds accounted for nearly 70% of sovereign investment into the region.
- • The rebound follows a 54% decline in 2025 driven by geopolitical tensions and concerns over China's economic outlook.
- • Investors are focusing on Chinese technology, biotechnology, consumer businesses and advanced manufacturing, with Mubadala citing attractive valuations and Temasek targeting biotech and AI-related hardware.
- • Despite the rebound, China and Hong Kong received just a fraction of the $132.4 billion that flowed to the U.S. in the same period.
Summary
Sovereign wealth funds are returning to mainland China and Hong Kong after a sharp 2025 slowdown, with Middle Eastern investors leading the recovery. According to data provided to CNBC by Global SWF, sovereign investments into the region reached $14.2 billion in the first nine months of 2026, a 190% increase over the funds' investments across all of 2025. The 2025 figure had itself reflected a 54% plunge from the prior year, as geopolitical tensions and concerns over China's economic outlook weighed on investor sentiment.
Middle Eastern sovereign investors have driven the resurgence. Saudi Arabia's Public Investment Fund accounted for $6 billion of the inflows, followed by Abu Dhabi Investment Authority with $2.5 billion, Mubadala with $800 million and Qatar Investment Authority with $600 million. Together, the four Gulf funds represented nearly 70% of sovereign investment into China and Hong Kong over the period. Qatar Investment Authority and Norway's sovereign wealth fund also participated in Alibaba's $10.2 billion share offering in August.
Sovereign investors are increasingly targeting Chinese technology, biotechnology, consumer businesses and advanced manufacturing. Andrew Wang, who leads the consumer division for private equity at Mubadala, said the fund sees China as its top priority for Asian consumer investments, citing "valuations are lower than they've been in years" and the potential for household consumption growth. Mubadala announced a minority investment in Luckin Coffee in September as part of a roughly $1 billion deal alongside Centurium Capital. Singapore's Temasek, which was a cornerstone investor in Zhongji Innolight's multibillion-dollar IPO in July, is focusing on biotechnology, domestic consumer brands and AI-related hardware. Temasek chief investment officer Rohit Sipahimalani said at the Milken Summit that "China continues to be interesting."
Jenny Lee, senior managing partner at Granite Asia, said China's strengths in manufacturing and biotechnology could give it an advantage as AI applications expand into robotics and drug discovery. Indonesia's Danantara is also seeking to broaden its cooperation with China beyond existing nickel processing and battery manufacturing partnerships, according to chief investment officer Pandu Sjahrir.
Despite the rebound, China remains a relatively small destination for sovereign capital. According to Global SWF, the U.S. attracted $132.4 billion in sovereign investments in the first nine months of 2026, versus $44.6 billion for Europe and the U.K.
Middle Eastern sovereign investors have driven the resurgence. Saudi Arabia's Public Investment Fund accounted for $6 billion of the inflows, followed by Abu Dhabi Investment Authority with $2.5 billion, Mubadala with $800 million and Qatar Investment Authority with $600 million. Together, the four Gulf funds represented nearly 70% of sovereign investment into China and Hong Kong over the period. Qatar Investment Authority and Norway's sovereign wealth fund also participated in Alibaba's $10.2 billion share offering in August.
Sovereign investors are increasingly targeting Chinese technology, biotechnology, consumer businesses and advanced manufacturing. Andrew Wang, who leads the consumer division for private equity at Mubadala, said the fund sees China as its top priority for Asian consumer investments, citing "valuations are lower than they've been in years" and the potential for household consumption growth. Mubadala announced a minority investment in Luckin Coffee in September as part of a roughly $1 billion deal alongside Centurium Capital. Singapore's Temasek, which was a cornerstone investor in Zhongji Innolight's multibillion-dollar IPO in July, is focusing on biotechnology, domestic consumer brands and AI-related hardware. Temasek chief investment officer Rohit Sipahimalani said at the Milken Summit that "China continues to be interesting."
Jenny Lee, senior managing partner at Granite Asia, said China's strengths in manufacturing and biotechnology could give it an advantage as AI applications expand into robotics and drug discovery. Indonesia's Danantara is also seeking to broaden its cooperation with China beyond existing nickel processing and battery manufacturing partnerships, according to chief investment officer Pandu Sjahrir.
Despite the rebound, China remains a relatively small destination for sovereign capital. According to Global SWF, the U.S. attracted $132.4 billion in sovereign investments in the first nine months of 2026, versus $44.6 billion for Europe and the U.K.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.